Product image of Niuliva (Human Hepatitis B Immunoglobulin) supplied by GNH India

Niuliva

Active Ingredient:
Human Hepatitis B Immunoglobulin
Origin:
EU

Niuliva (Human Hepatitis B Immunoglobulin)

Human Hepatitis B Immunoglobulin, the active ingredient in Niuliva, is an immunoglobulin presented as a sterile intravenous solution for intravenous use. It provides passive immunity to individuals at risk of hepatitis B infection, including those exposed to the virus or newborns of infected mothers.

GNH India supplies Niuliva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory‑approved product documentation to support global distribution.

Manufacturer / TM Owner

Instituto Grifols, S.A.

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

  • Niuliva, a human hepatitis B immunoglobulin, provides passive immunity against hepatitis B virus by delivering anti‑HBs antibodies.
  • Post‑exposure prophylaxis after potential hepatitis B exposure: prevents infection by supplying immediate anti‑HBs antibodies while active vaccination takes effect.
  • Prevention of mother‑to‑child transmission in newborns of HBsAg‑positive mothers: reduces perinatal infection risk during the critical first weeks of life.
  • Protection for individuals at high risk of hepatitis B after known exposure: offers immediate immunity pending development of active vaccine‑induced protection.

How It Works

  • Human hepatitis B immunoglobulin consists of pooled IgG antibodies containing high titres of anti‑hepatitis B surface (anti‑HBs) antibodies. After intravenous infusion, these antibodies bind to circulating hepatitis B virus particles, neutralizing their ability to infect hepatocytes and facilitating clearance by the reticuloendothelial system. By supplying passive immunity, the product bridges the gap until the recipient’s own immune response, stimulated by active vaccination, becomes effective.

Side Effects

Human hepatitis B immunoglobulin may be associated with a range of infusion‑related reactions, varying from mild to severe.

Common Side Effects

  • Fever: transient rise in body temperature.
  • Chills: shaking sensation during or after infusion.
  • Headache: mild to moderate discomfort.
  • Nausea: occasional upset stomach.

Serious or Rare Side Effects

  • Anaphylaxis: severe allergic reaction requiring immediate medical intervention.
  • Renal dysfunction: impaired kidney function observed in rare cases.

Precautions & Warnings

When using Niuliva, clinicians should observe several precautionary measures to ensure patient safety and product integrity.

  • Allergy assessment: verify no known hypersensitivity to human immunoglobulins.
  • Renal function monitoring: assess kidney status in patients with pre‑existing impairment.
  • Pregnancy and lactation: use only if the expected benefit outweighs potential risk.
  • Concurrent immunoglobulin therapy: avoid overlapping infusions unless medically justified.
  • Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Avoid Interactions

Niuliva may interact with other agents; awareness of potential interactions helps maintain therapeutic effectiveness.

Major Interactions (Avoid)

  • Concurrent administration of blood products containing anti‑HBs antibodies: may cause immune complex formation.
  • Live attenuated vaccines: may reduce vaccine efficacy; schedule appropriately.
  • Immunosuppressive therapy: may diminish the protective effect of passive antibodies.

Moderate Interactions (Monitor Closely)

  • Heparin therapy: monitor for additive anticoagulant effect and bleeding risk.
  • Vaccination within two weeks of infusion: monitor antibody response and consider timing adjustments.

Frequently Asked Questions

Niuliva is a human hepatitis B immunoglobulin administered intravenously to provide passive immunity against hepatitis B virus. It is used for post‑exposure prophylaxis, to protect newborns of HBsAg‑positive mothers, and for individuals at high risk of infection after known exposure.

The product contains pooled IgG antibodies with high titres of anti‑HBs (hepatitis B surface) antibodies. After infusion, these antibodies bind to circulating hepatitis B virus particles, neutralizing them and promoting clearance, thereby offering immediate protection while the patient’s own immune response develops.

The dose of Niuliva is determined by the prescribing healthcare professional based on the patient’s weight, age, exposure risk and clinical guidelines. Specific dosing regimens are not disclosed here and should be obtained from the treating physician.

Safety data for Niuliva in pregnancy and lactation are limited. It should be used only if the potential benefit to the mother or infant outweighs any possible risk, and the decision must be made by a qualified healthcare provider.

To order Niuliva, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain handling) and necessary import documentation.

Niuliva provides passive immunity through anti‑HBs antibodies, offering immediate protection. Unlike active vaccines, it does not induce long‑term immunity but is essential for rapid protection after exposure or in newborns. Compared with other hepatitis B immunoglobulins, its efficacy and safety profile are similar, with choice often based on availability, formulation and regulatory approvals.

Niuliva must be stored at 2‑8 °C, protected from light, and should not be frozen or shaken. It should be kept in its original packaging until use to maintain stability and potency.

Niuliva is given as an intravenous infusion under the supervision of a qualified healthcare professional. The infusion rate and duration are determined by the prescriber, and patients are monitored for any infusion‑related reactions during and after administration.

The most serious risks include severe allergic reactions such as anaphylaxis and rare cases of renal dysfunction. Prompt recognition and immediate medical intervention are essential if signs of a serious reaction occur.

Niuliva should not be administered to individuals with a known hypersensitivity to human immunoglobulin products or any of its excipients. Caution is also advised for patients with severe renal impairment, and the decision to treat should be made by a healthcare professional.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Human Hepatitis B Immunoglobulin

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT